- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03101631
Frailty Evaluation in Elderly Population With Cancer (ELDERLY)
Exploratory Study of Frailty Evaluation in Elderly Population With Cancer
Study Overview
Status
Intervention / Treatment
Detailed Description
This study compares two groups of elderly patients affected with stage IV non-small lung cancer (NSCLC), stage III colon cancer and stage IV colorectal cancer (CRC): a prospective experimental cohort and an historic control cohort. The sample size is 60 patients, 30 prospective and 30 retrospective. Of each cohort, 10 patients have stage IV NSCLC, 10 have stage III colon cancer and 10 have stage IV CRC. Prospective patients will be recruited longitudinally from January 2013 and retrospective patients are recorded longitudinally backward in time from December 2012. Both groups are patients of Medical Oncology Service of Hospital General Universitario de Elche, and both groups sign an informed consent form.
A CGA is performed in the experimental group after the first visit with oncologist and prior to therapeutic decision. This CGA includes:
- Nutritional Assessment: Mini Nutritional Assessment (MNA)
- Functional Assessment: Get up and Go, Activities of Daily Living (ADL), Instrumental Activities of Daily Living (IADL), Karnofsky Scale, Walking one Block, Number of Falls in last 6 months and Hearing Loss.
- Cognitive Assessment: Mini-Mental State Examination (MMSE-30)
- Psychological status: Geriatric Depression Scale (GDS)
- Social Support: Medical Outcomes Study Social Support Survey (MOS-SSS)
- Comorbidity and Severity of Comorbidities: Charlson Comorbidity Index and Adult Comorbidity Evaluation (ACE-27)
The evaluation includes too age, haemoglobin, Creatinine Clearance (CrCl) and presence of geriatric syndromes.
The results of this evaluation allow to calculate:
- Early mortality risk according to Soubeyran et al (JCO 2012, 30: 1829-1834) (MNA and Get up and Go):
- risk of early mortality
- no risk of early mortality.
- Toxicity to chemotherapy according to Hurria et al. (J Clin Oncol 2011, 29: 3457-3465) (age, type of cancer, dose and number of chemotherapy drugs, haemoglobin, CrCl, hearing loss, number of falls in last 6 months, ability to take medication without help (IADL), walking one block and social support (MOS-SSS):
- low risk
- medium risk
- high risk.
- Frailty group according Köhne et al (The Oncologist 2008, 13: 390-402) (ADL, IADL, comorbidity and severity of comorbidities and presence of geriatric syndromes). This information dictates the therapeutic strategy for each experimental patient:
- Group 1: standard treatment.
- Group 2: modified treatment
- Group 3: no treatment
Experimental patients will be followed for six months from CGA and their toxicity and its severity, occurrence of treatment modifications, number of hospitalizations and reasons for hospitalizations and mortality and reason of mortality will be compared with the same items of historic controls, followed too for six months from the moment the physician made the therapeutic decision.
Other data to record for both groups: sex, age, origin, leucocytes, platelets, LDH, albumin, CEA, Cr Cl, haemoglobin, subjective weight loss, corporal mass index, comorbidities, primary tumor: stage, metastases location, treatment intent: adjuvant, palliative, number of drugs, number of concomitant medications, PS according to ECOG and Karnofsky (some data are expected to be missing for historic group).
Only for historic controls, physicians should answer one question : In wich category would include the treatment recommendation? according to Köhne, The Oncologist 2008: Balducci, The Oncologist 2000; J Clin Oncol 2012:
- standard treatment
- modified treatment
- no treatment despite treatment is recommended
- no treatment
Only for historic controls two more questions should be answered:
- Has a Geriatric Evaluation been performed? Yes or No
- What sort of evaluation?
The trial records too how long does it take each test and how long does it take to complete CGA.
All information is recorded in a database with anonymous code for each subject.
Statistical analysis will consist of a descriptive analysis of sociodemographic and clinical characteristics of both cohorts. It will be performed also non-parametric analysis comparing this characteristics between the experimental groups. A descriptive analysis of daily life characteristics in experimental group will be performed, and also a non-parametric analysis comparing these variables between the experimental groups.
Changes due to CGA incorporation will be evaluated and the variables measuring the toxicity and early mortality should be correlated to the coincidence or not of the treatment performed with the one concluded by the geriatric evaluation.
Contribution of the different elements of CGA will be evaluated. A multiple regression will be performed in order to carry out an evaluation of the degree of contribution of each of the elements of the CGA.
A significance "p" less than 0.05 will be considered significant.
There are some study limitations: size, missing data for historic patients, monocentric study.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age more than 70 years
- Outpatients
- Patients diagnosed with stage III colon cancer, stage IV colorectal cancer or stage IV NSCLC
- No previous diagnosis of cancer.
- No previous chemotherapy for current diagnosis of cancer
- Signed informed consent
Exclusion Criteria:
- Not fulfilling inclusion criteria
Study Plan
How is the study designed?
Design Details
- Primary Purpose: SCREENING
- Allocation: NON_RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: CASE ARM
This is a three cohorts arm with intervention (CGA):
|
CGA includes a set of evaluations to determine therapeutic decision based on mortality risk, toxicity risk and frailty group. Evaluations includes:
Other Names:
|
NO_INTERVENTION: CONTROL ARM
This is a three cohorts arm with no intervention
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of participants with treatment related adverse events as assessed by CTCAE v4.0
Time Frame: 6 months
|
Evaluate occurrence of toxicity in both groups, experimental and control
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of participants with occurrence of early mortality
Time Frame: 6 months
|
Evaluate occurrence of early mortality in both groups, experimental and control
|
6 months
|
Number of Hospitalizations
Time Frame: 6 months
|
Evaluate occurrence of hospitalizations in both groups, experimental and control
|
6 months
|
Number of participants with changes in cancer treatment related to toxicity
Time Frame: 6 months
|
Evaluate changes in treatment in both groups, experimental and control
|
6 months
|
Number of participants with a change in therapeutic decision related to CGA
Time Frame: 6 months
|
Evaluate impact in the treatment for cancer in elderly population with NSCLC stage IV, colon cancer stage III and CRC stage IV of a CGA
|
6 months
|
Contribution of different components of CGA to the management fo cancer
Time Frame: 6 months
|
Analysis of the weight of ech component through multiple regression
|
6 months
|
Impact of CGA in health care in terms of human recourses and time consumption
Time Frame: Baseline
|
Cost of CGA measured in minutes for each component of CGA and person
|
Baseline
|
Predictive factors of events related to treatment
Time Frame: 6 months
|
To detect wich conditions predispose to adverse events
|
6 months
|
Collaborators and Investigators
Publications and helpful links
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- ELDERLY V 1.0 20DEC2012
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cancer
-
Cellworks Group Inc.RecruitingCancer | Relapsed Cancer | Refractory CancerUnited States
-
University of Michigan Rogel Cancer CenterRecruitingCancer Liver | Cancer Brain | Cancer Head &Neck | Cancer PelvisUnited States
-
UNC Lineberger Comprehensive Cancer CenterHyundai Hope On WheelsRecruitingCancer | Pediatric Cancer | Survivorship | Cancer MetastaticUnited States
-
Vanderbilt-Ingram Cancer CenterNational Institutes of Health (NIH)Active, not recruitingAdvanced Cancer | Relapsed Cancer | Refractory CancerUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)CompletedStage III Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IV Gastric Cancer | Stage IVA Colorectal Cancer | Stage IVA Pancreatic Cancer | Stage IVB Colorectal Cancer | Stage IVB Pancreatic Cancer | Stage IIIA Gastric Cancer | Stage IIIB Gastric Cancer | Stage IIIC Gastric... and other conditionsUnited States
-
MiRXES Pte LtdRecruitingBreast Cancer | Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Esophageal Cancer | Ovarian Cancer | Prostate Cancer | Thoracic Cancer | Liver CancerSingapore
-
Sidney Kimmel Cancer Center at Thomas Jefferson...CompletedStage I Breast Cancer | Stage I Uterine Corpus Cancer | Stage II Uterine Corpus Cancer | Stage III Uterine Corpus Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage... and other conditionsUnited States
-
University of California, San FranciscoBristol-Myers Squibb; PfizerTerminatedStage IIIA Rectal Cancer | Stage IIIB Rectal Cancer | Stage IIIC Rectal Cancer | Metastatic Colorectal Adenocarcinoma | Metastatic Colon Adenocarcinoma | Metastatic Rectal Adenocarcinoma | Stage IIIA Colon Cancer | Stage IIIB Colon Cancer | Stage IIIC Colon Cancer | Stage IV Colon Cancer | Stage IV Rectal... and other conditionsUnited States
-
Massachusetts General HospitalNational Comprehensive Cancer NetworkCompletedGastric Cancer | Pancreatic Cancer | Esophageal Cancer | Rectal Cancer | Colon Cancer | Hepatobiliary CancerUnited States
-
Johns Hopkins UniversityNational Cancer Institute (NCI); National Institute on Minority Health and...Enrolling by invitationCancer | Advanced Cancer | End Stage Cancer | MalignancyUnited States
Clinical Trials on Comprehensive Geriatric Assessment (CGA)
-
The University of Texas Health Science Center at...RecruitingCharacterizing Disease Biology, Treatment and Toxicity in Older Adults With Hepatocellular CarcinomaCarcinoma, HepatocellularUnited States
-
The University of QueenslandNational Health and Medical Research Council, AustraliaRecruitingChronic Kidney Diseases | FrailtyAustralia
-
Assistance Publique - Hôpitaux de ParisRecruitingStem Cell TransplantFrance
-
Assistance Publique Hopitaux De MarseilleCompleted
-
Linkoeping UniversityRegion Östergötland; Region Jönköping CountyActive, not recruiting
-
Sahlgrenska University Hospital, SwedenRecruitingColorectal Neoplasms | Frailty | CGASweden
-
Fundació Institut de Recerca de l'Hospital de la...Fundació Mutuam ConviureUnknownEmergencies | Aging | Geriatric Assessment | Patient DischargeSpain
-
University of AarhusAarhus University Hospital; Horsens Hospital; Randers Regional Hospital; Central...CompletedFrail Elderly | Aged | Geriatric Assessment | Clostridioides Difficile | Faecal Microbiota TransplantationDenmark
-
Gulhane Training and Research HospitalEnrolling by invitationMuscle Weakness | Frail Elderly SyndromeTurkey
-
University of AarhusCompletedModels of Care in the Transition From the Secondary to the Primary Sector Among the Frailest ElderlyFrail Elderly Syndrome | Frailty | Aging | Elderly | Readmission | Transitional CareDenmark